QDEL · Categories · Conferences
QDEL - Conference and earnings call announcements
QuidelOrtho Corporation (QDEL) conference and earnings call announcements - real-time wire coverage filtered to Conferences only.
Recent Conferences for QDEL
- QuidelOrtho to Participate in Upcoming June 2026 Investor ConferencesSAN DIEGO, May 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 46th Annual Growth Stock Conference, Tuesday, June 2, 2026Members of QuidelOrtho's management team will participate in a presentation at 12:20 p.m. ET / 9:20 a.m. PT.Jefferies Global Healthcare Conference, Wednesday, June 3, 2026Members of QuidelOrtho's management team will participate in a fireside
- QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor ConferenceSAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced that members of its management team will present at the Raymond James 47th Annual Institutional Investor Conference. The Company's presentation is scheduled for Tuesday, March 3, 2026, at 1:40 p.m. ET / 10:40 a.m. PT. Interested parties can access the live webcast and replay in the "Events & Presentations" section of the "Investor Relations" page of QuidelOrtho's website at https://ir.quidelortho.com/
- QuidelOrtho To Participate In Upcoming Investor ConferencesSAN DIEGO, Nov. 24, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global leader of in vitro diagnostics, announced today that members of its management team will participate in two upcoming investor conferences: Evercore ISI 8th Annual Healthcare Conference, Tuesday, December 2, 2025Members of QuidelOrtho's management team are scheduled to participate in a fireside chat at 10:00 a.m. ET / 7:00 a.m. PT.Citi Global Healthcare Conference, Wednesday, December 3, 2025Members of QuidelOrtho's management team are scheduled to participate in a fireside
- QuidelOrtho to Participate in the Baird 2025 Global Healthcare ConferenceSAN DIEGO, Aug. 28, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025. The Company's fireside chat will begin at 3:10 p.m. ET / 12:10 p.m. PT. Interested parties can access the live webcast and replay in the "Events & Presentations" section of the "
- QuidelOrtho to Participate in Upcoming Investor ConferencesQuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 45th Annual Growth Stock Conference, Wednesday, June 4, 2025 Members of QuidelOrtho's management team will participate in a presentation at 9:00 a.m. ET / 6:00 a.m. PT. Jefferies Global Healthcare Conference, Thursday, June 5, 2025 Members of QuidelOrtho's management team will participate in a fireside chat at 8:45 a.m. ET / 5:45 a.m. PT. Interested parties can access the liv
- QuidelOrtho to Participate in the 46th Annual Raymond James Institutional Investor ConferenceQuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 46th Annual Raymond James Institutional Investor Conference on Wednesday, March 5, 2025. Members of QuidelOrtho's management team will participate in a presentation at 8:40 a.m. ET / 5:40 a.m. PT. Interested parties can access the live webcast and replay in the "Events & Presentations" section of the "Investor Relations" page of QuidelOrtho's website at https://ir.quidelortho.com. About QuidelOrtho Corporation QuidelOr
- NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business UpdatesPreliminary unaudited revenue expected to be between $21.0 million and $21.5 million for Q4 2024, and between $79.4 million and $79.9 million for full year 2024 Scott Huennekens Appointed to NeuroPace Board of Directors effective January 6th Management presenting at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th Company to host an Investor Day on January 28th in New York City MOUNTAIN VIEW, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced preliminary unaudited revenue for the quarter and year ended December 31, 20
- QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceQuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. The Company's presentation is scheduled for Monday, January 13, 2025 at 7:30 a.m. PST / 10:30 a.m. EST. Interested parties can access the live webcast and replay in the "Events & Presentations" section of the "Investor Relations" page of QuidelOrtho's website at https://ir.quidelortho.com/. About QuidelOrtho Corporation QuidelOrtho Corporation (NASDAQ:QDEL) is a world
- QuidelOrtho to Participate in Three Upcoming Investor ConferencesQuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will attend three upcoming investor conferences and participate in fireside chats at all three conferences. UBS Global Healthcare Conference On Tuesday, November 12, 2024, QuidelOrtho is scheduled to participate in a fireside chat at 2:00 p.m. ET / 11:00 a.m. PT at the conference in Rancho Palos Verdes, California. Citi 2024 Global Healthcare Conference On Wednesday, December 4, 2024, QuidelOrtho is scheduled to participate in
- QuidelOrtho to Participate in Upcoming Investor ConferencesQuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will attend two upcoming investor conferences. Morgan Stanley 22nd Annual Global Health Conference – New York, NY On Thursday, September 5, 2024, QuidelOrtho's President and Chief Executive Officer, Brian Blaser, and Chief Financial Officer, Joseph Busky, are scheduled to participate in a fireside chat at 7:00 a.m. ET / 4:00 a.m. PT. 2024 Baird Global Healthcare Conference – New York, NY On Tuesday, September 10, 2024, Messrs. Blaser and
- QuidelOrtho to Participate in 44th Annual William Blair Growth Stock ConferenceQuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced that members of its management team are scheduled to participate in the 44th Annual William Blair Growth Stock Conference on June 5, 2024, in Chicago, IL. The Company will host a presentation at 1:20 p.m. CT. Interested parties can access the live webcast and replay in the "Events & Presentations" section of the "Investor Relations" page of QuidelOrtho's website at https://ir.quidelortho.com/. About QuidelOrtho Corporation QuidelOrtho Corporation (NASDAQ:QDEL
- QuidelOrtho to Participate in 45th Annual Raymond James Institutional Investor ConferenceQuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced that members of its management team are scheduled to participate in the 45th Annual Raymond James Institutional Investor Conference on March 5, 2024, in Orlando, FL. Recently named Interim Chief Executive Officer, Michael Iskra, and Interim President, Robert Bujarski, will join Chief Financial Officer, Joseph Busky, in a brief presentation followed by a fireside chat at 4 p.m. ET / 1 p.m. PT. Interested parties can access the live webcast and replay in the "Events & Presentatio
- QuidelOrtho to Present at 42nd Annual J.P. Morgan Healthcare ConferenceQuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced that Douglas Bryant, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, in San Francisco, CA, scheduled for 12:00 p.m. ET / 9:00 a.m. PT. Interested parties can access the live webcast and replay on the "Events & Presentations" section of the "Investor Relations" page of QuidelOrtho's website at https://ir.quidelortho.com/. About QuidelOrtho Corporation QuidelOrtho Corporation (NASDAQ:QDEL) is a world leader
- QuidelOrtho to Participate in the Evercore ISI ConferenceQuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Evercore ISI conference in Miami, FL, on November 30, 2023. Douglas Bryant, President and Chief Executive Officer, will participate in a fireside chat scheduled for 9:10 a.m. ET / 6:10 a.m. PT. Interested parties can access the live webcast and replay, which will be available for 90 days, on the "Events & Presentations" section of the "Investor Relations" page of QuidelOrtho's website at https://ir.quidelo
- QuidelOrtho to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceQuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023. Douglas Bryant, President and Chief Executive Officer, and Joseph Busky, Chief Financial Officer, will participate in a fireside chat scheduled for 2:55 p.m. ET / 11:55 a.m. PT. Interested parties can access the live webcast and replay on the "Events & Presentations" section of the "Investor Relations" page of Quidel
- QuidelOrtho to Participate in William Blair 43rd Annual Growth Stock ConferenceQuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the William Blair 43rd Annual Growth Stock Conference in Chicago, Illinois, on June 6, 2023. A presentation will be given by Douglas Bryant, President and Chief Executive Officer, and Joseph Busky, Chief Financial Officer, scheduled for 2:00 p.m. CT/12:00 p.m. PT. Interested parties can access the live webcast and replay on the "Events & Presentations" section of the "Investor Relations" page of QuidelOrtho's
- QuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor ConferenceQuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Raymond James & Associates' 44th Annual Institutional Investors Conference in Orlando, Florida, on March 7, 2023. Douglas Bryant, president and chief executive officer, will present in a fireside chat format scheduled for 11:35 a.m. ET / 8:35 a.m. PT. Interested parties can access the live webcast and replay on the "Events & Presentations" section of the "Investor Relations" page of QuidelOr
- QuidelOrtho to Present at the J.P. Morgan Healthcare ConferenceQuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco beginning on January 9, 2023, with a presentation scheduled for 9:00 a.m. PST / 12:00 p.m. EST. Interested parties can access the live webcast and replay on the "Events & Presentations" section of the "Investor Relations" page of QuidelOrtho's website at https://ir.quidelortho.com/. About QuidelOrtho Corporation QuidelOrtho Corporation (NASDAQ:Q
- Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel CorporationLyme disease is the fastest-growing vector-borne disease in the United States, and its increased prevalence is challenging the scientific community to look for new ways to diagnose and treat this worrisome infection. One answer is found in the discovery of novel drugs; and the breakthrough efforts taking place in this arena are the subject of a new webinar made available by Quidel Corporation, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions. The 90-minute webinar, available free at https://education.quidel.com/category/lyme-disease, will explain what a small molecule drug is and how it works, identify the metho
- QuidelOrtho to Participate in the Morgan Stanley 20th Annual Global Healthcare ConferenceQuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Morgan Stanley 20th Annual Global Healthcare Conference in New York beginning on September 12, 2022, with a fireside chat scheduled for 4:50 p.m. ET / 1:50 p.m. PT. Interested parties can access the live webcast and replay on the "Events & Presentations" section of the "Investor Relations" page of QuidelOrtho's website at https://ir.quidelortho.com/. About QuidelOrtho Corporation QuidelOrtho Corporation (NA
- Bacterial Biofilms, Responsible for Up to 75% of All Infectious Diseases in America, Explored in New Webinar From Quidel CorporationThe National Institutes of Health reports that bacterial biofilms are responsible for up to 75% of all infectious diseases in humans, including infections of wounds, the lungs and the urinary tract. This important medical reality is now being addressed in a new webinar made available by Quidel Corporation, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions. The webinar, available at https://education.quidel.com/educational-categories, discusses the basics of bacterial biofilms including when and how they develop, its composition and factors that contribute to antibiotic resistance and virulence. The session also expl
- QuidelOrtho Formed by the Completion of Transaction Combining Quidel and Ortho Clinical DiagnosticsQuidelOrtho to participate in the William Blair 42nd Annual Growth Stock Conference June 8, 2022 QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho") announced completion of the transaction combining Quidel Corporation ("Quidel") and Ortho Clinical Diagnostics Holdings plc ("Ortho"), creating QuidelOrtho, a leading in vitro diagnostics company. The new company, headquartered in San Diego, California, generated more than $3.5 billion in combined revenues in 2021 and has approximately 6,000 employees. QuidelOrtho will trade on the Nasdaq Global Select Market under the symbol "QDEL." "We are very excited to bring together the talented and experienced teams of both Quidel and Ortho who share
- Quidel to Present at Raymond James 43rd Annual Institutional Investors ConferenceQuidel Corporation (NASDAQ:QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Raymond James & Associates 43rd Annual Institutional Investors Conference to be held at the J.W. Marriott Orlando Grande Lakes hotel in Orlando, Florida on Wednesday, March 9, 2022 at 10:25 a.m. Eastern Time (7:25 a.m. Pacific Time). Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on March 9th with a question-and-answer session scheduled immediately following the presentation. During the presentation, the company will discuss bus
- Quidel Announces Preliminary Revenue for Fourth Quarter 2021Quidel to Present Virtually at 40th Annual J.P. Morgan Healthcare Conference Quidel Corporation (NASDAQ:QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects total revenues in the fourth quarter of 2021 to be in the range of $633 million to $637 million and full year total revenues to be in the range of $1,695 million to $1,699 million. COVID-19 revenues in the fourth quarter of 2021 are expected to be approximately $510 million. "The fourth quarter of 2021 put the final exclamation point on a truly outstanding and transformational year for Quidel," said Douglas Bryant, President
- The Signs, Diagnosis and Treatment of Lyme Disease Discussed as Part of New, On-Demand Webinar Hosted by Industry-Leading Quidel CorporationAn important public health webinar focused on the Bartonella species, the bacterium that causes Bartonellosis, is now available on demand at https://education.quidel.com/educational-categories. Borrelia burgdorferi, the bacterium that causes Lyme disease, is also discussed as a coinfection on this PACE-accredited webinar, the third in a series hosted by Quidel Corporation (NASDAQ:QDEL) in collaboration with Global Lyme Alliance. Titled "The Diversity of Bartonellosis Manifestations and Challenges to Treatment," the webinar is conducted by Monica E. Embers, Ph.D.,* associate professor of microbiology and immunology and director of vector-borne disease research at Tulane National Primate Res
- Quidel to Present at 40th Annual J.P. Morgan Healthcare ConferenceQuidel Corporation (NASDAQ:QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference to be held virtually on Wednesday, January 12, 2022. Douglas Bryant, president and chief executive officer, will present that day at 1:30 p.m. Eastern time (10:30 a.m. Pacific time) with a question-and-answer session scheduled immediately following the presentation. During the presentation, the company will discuss business and financial developments and trends. The company's statements may contain or constitute material information that has not been previous
- Pediatric Lyme Disease—'An Epidemic Within a Pandemic!'—to be Focus of Free Webinar Hosted by Quidel Corporation Oct. 21Among the many health challenges facing children is the very real threat of contracting Lyme disease as nearly 30% of the estimated 476,000 people in the U.S. each year who are diagnosed and treated for this disease are ages 0-19. In response to this troubling fact, an important webinar focused on how Lyme disease affects the pediatric population will be held on Thursday, Oct. 21. The free webinar—titled Pediatric Lyme Disease: "An Epidemic Within a Pandemic!"—is part of an ongoing series hosted by Quidel, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions. The program is being held in collaboration with the Global L
- LivLyme Foundation Founder Olivia Goodreau to Discuss Perils of Lyme Disease in Free Webinar Hosted by Industry-Leading Quidel CorporationOlivia Goodreau, who founded the LivLyme Foundation at 12 years old and has since become a widely respected advocate and national spokeswoman for Lyme disease prevention and treatment, will discuss her "journey with Lyme" and the importance of early testing as part of a webinar to be held Thursday, Aug. 19. The webinar is the latest in an ongoing series sponsored by Quidel, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions. Webinar Registration The free online educational program will take place Aug. 19 at noon EDT. Registration is available now at https://education.quidel.com/registration/2580/1/r/LD-1. You
- Teaching Doctors Nationwide How to Recognize and Differentiate Between Lyme Disease, COVID-19 and the Flu in Quidel-Hosted May 5 WebinarWith Lyme disease season emerging and the COVID-19 pandemic still with us, an important webinar designed to help physicians differentiate between the two (as well as the flu) so as to provide timely diagnosis and treatment for their patients will be held on Wednesday, May 5. The webinar is the latest in an ongoing series sponsored by Quidel, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions. Titled "Solve the Great Imitators: Is it COVID-19, Tick-Borne Disease or the Flu?," the webinar will be conducted by Sean McCloy,* M.D., M.P.H., M.A., national thought leader and medical director at the Integrative Health Center
- Quidel to Present at Upcoming ConferencesSAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the following upcoming conferences: Raymond James & Associates 42nd Annual Institutional Investors Conference to be held virtually on Tuesday, March 2, 2021 at 11:40 a.m. Eastern Time (8:40 a.m. Pacific Time). Barclays Global Healthcare Conference, to be held virtually on Wednesday, March 10, 2021 at 1:15 p.m. Eastern Time (10:15 a.m. Pacific Time). Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will pre
- Quidel Reports Fourth Quarter and Full Year 2020 Financial ResultsSAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and year ended December 31, 2020. Fourth Quarter 2020 Highlights Total revenue increased 432% to $809.2 million, from $152.2 million in the fourth quarter of 2019. Revenue for COVID-19 products was $678.7 million. Reported GAAP EPS of $10.78 per diluted share in the fourth quarter of 2020, compared with $0.71 per diluted share in the fourth quarter of 2019. Reported non-GAAP EPS of $11.07 per diluted share in the fourth quarter of 2020, comp
- Quidel to Hold Fiscal Fourth Quarter and Full Year 2020 Financial Results Conference Call on February 18th, 2021SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal fourth quarter and full year 2020 financial results after market close on Thursday, February 18, 2021. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the results and answer questions. During the conference call, the company will also discuss business and financial developmen
- Quidel Announces Preliminary Revenue for Fourth Quarter 2020; Will Present Virtually at 39th Annual J.P. Morgan Healthcare ConferenceSAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenues in the fourth quarter of 2020 to be in the range of $808 million to $810 million, up from $476 million in the prior quarter. “The COVID-19 pandemic has presented challenges to all companies. At Quidel, our people have responded at every level and function -- from R&D and regulatory to supply chain and manufacturing. Due to the hard work and dedication of our people, we had another record quarter, and our best year yet,” said Douglas Bryant, president and